Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Hand-out
Press Releases
Spyre Therapeutics, Inc.  
November 7, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter

avatar profile Olean Times Herald

Olean Times Herald


Local & Social